Yuko Palesch to Fibrinolytic Agents
This is a "connection" page, showing publications Yuko Palesch has written about Fibrinolytic Agents.
Connection Strength
1.462
-
Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013 06 20; 368(25):2432-3.
Score: 0.347
-
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 02 22; 378(8):708-718.
Score: 0.119
-
Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
Score: 0.114
-
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016 Feb; 47(2):581-641.
Score: 0.103
-
Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
Score: 0.098
-
Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. J Neurointerv Surg. 2015 Nov; 7(11):795-802.
Score: 0.095
-
Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials. Stroke. 2014 Dec; 45(12):3606-11.
Score: 0.095
-
Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014 Oct; 273(1):202-10.
Score: 0.093
-
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
Score: 0.085
-
Covariate imbalance and adjustment for logistic regression analysis of clinical trial data. J Biopharm Stat. 2013; 23(6):1383-402.
Score: 0.084
-
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis. Stroke. 2006 Aug; 37(8):2107-14.
Score: 0.054
-
Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. Stroke. 2015 Feb; 46(2):461-4.
Score: 0.024
-
Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):567-74.
Score: 0.023
-
Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
Score: 0.023
-
Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014 Mar; 45(3):759-64.
Score: 0.023
-
Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014 Feb; 45(2):444-9.
Score: 0.022
-
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke. 2010 Apr; 41(4):732-8.
Score: 0.017
-
Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008 May; 3(2):130-7.
Score: 0.015
-
The albumin in acute stroke trial (ALIAS); design and methodology. Int J Stroke. 2007 Aug; 2(3):214-9.
Score: 0.014
-
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Stroke. 2006 Aug; 37(8):2100-6.
Score: 0.013